{"transactions":[{"id":178183,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock Warrants (Right To Buy)","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"other","acquired":false,"shares":13355,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":6.4022,"underlying":"Common Stock","underlying_shares":13355},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178182,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"price":0,"reported_value":279103,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":41823},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178181,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"shares":117361,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":117361},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178180,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"shares":108932,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":108932},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178179,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Notes","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":false,"price":0,"reported_value":3000000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."}],"balance_after":0,"derivative":{"exercise_price":7,"underlying":"Common Stock","underlying_shares":448767},"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178178,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"purchase","acquired":true,"shares":272142,"price":7,"value":1904994.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":541399,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178177,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"other","acquired":true,"shares":1141,"price":6.4022,"value":7304.9102,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"In accordance with the terms of the Warrant to Purchase Equity Securities, the warrant was net exercised and based on a fair market value of $7.00 per share, a net of 1,141 shares were acquired by Ventures."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":269257,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178176,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":true,"shares":268116,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Ventures"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Owned directly by Amgen Ventures LLC (\"Ventures\"), a wholly-owned subsidiary of Amgen Inc. (\"Amgen\").  Amgen may be deemed to beneficially own securities held by Ventures, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein."}],"balance_after":268116,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":178175,"issuer":{"id":12646,"kind":"organization","name":"TETRALOGIC PHARMACEUTICALS Corp","symbol":"TLOG"},"owners":[{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":1,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":2,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-12-18T23:09:59.000Z","date":"2013-12-17","kind":"exercise","acquired":true,"shares":448767,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-191811) (the \"Registration Statement\"), in connection with the Issuer's initial public offering (the \"Offering\"), upon the closing of the Offering, (i) each outstanding share of the Issuer's preferred stock was converted on a one-for-one basis into the Issuer's common stock, (ii) certain warrants for the right to purchase Series C Convertible Preferred Stock were exercised on a one-for-one basis at the exercise price reported herein and converted into common stock of the Issuer on a one-for-one basis, and (iii) the Issuer's common stock was issued upon conversion of the convertible notes by dividing the face value of such notes plus accrued interest due on such notes by the initial public offering price of the Issuer's common stock."}],"balance_after":448767,"source":{"system":"sec-edgar","filing":"0001181431-13-063433","document":"rrd395732.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113063433/rrd395732.xml","form_type":"4"}},{"id":183480,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":1,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2013-06-05T20:01:48.000Z","date":"2013-06-05","kind":"exercise","acquired":false,"shares":952381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares.  Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":317460},"source":{"system":"sec-edgar","filing":"0001181431-13-032856","document":"rrd380749.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113032856/rrd380749.xml","form_type":"4"}},{"id":183479,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":1,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-06-05T20:01:48.000Z","date":"2013-06-05","kind":"purchase","acquired":true,"shares":16666,"price":15,"value":249990.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares.  Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":334126,"source":{"system":"sec-edgar","filing":"0001181431-13-032856","document":"rrd380749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113032856/rrd380749.xml","form_type":"4"}},{"id":183478,"issuer":{"id":12703,"kind":"organization","name":"Epizyme, Inc.","symbol":"EPZM"},"owners":[{"id":12647,"kind":"organization","name":"Amgen Ventures LLC","position":1,"cik":"0001576997","reported_name":"Amgen Ventures LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":2832,"kind":"organization","name":"AMGEN INC","symbol":"AMGN","position":2,"cik":"0000318154","reported_name":"AMGEN INC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2013-06-05T20:01:48.000Z","date":"2013-06-05","kind":"exercise","acquired":true,"shares":317460,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares.  Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock."}],"balance_after":317460,"source":{"system":"sec-edgar","filing":"0001181431-13-032856","document":"rrd380749.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/318154/000118143113032856/rrd380749.xml","form_type":"4"}}]}